Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04819373 · ClinicalTrials.gov registry record · Phase 2
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
A Phase 2 study, sponsored by Eikon Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04819373: Completed Phase 2 study, sponsored by Eikon Therapeutics.
NCT04819373 is a Phase 2 study that has completed, run by Eikon Therapeutics. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04819373, a Phase 2 study, has completed, sponsored by Eikon Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
BDB001-201 is a multi-center, open-label, Phase II clinical trial to evaluate the efficacy and safety of BDB001 in the treatment of subjects with advanced solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment.
Primary Outcome
Objective Response Rate
Interventions
- DRUG BDB001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2023-05-01 |
| Phase | Phase 2 |
What the finished NCT04819373 record still lists
NCT04819373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which BDB001 is the first listed.
NCT04819373 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04819373 about?
NCT04819373 is a clinical study titled "BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors". BDB001-201 is a multi-center, open-label, Phase II clinical trial to evaluate the efficacy and safety of BDB001 in the treatment of subjects with advanced solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment.
What is the current status of trial NCT04819373?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2021-08-30. Estimated completion is 2023-05-01.
What interventions are being tested in trial NCT04819373?
The interventions under investigation include: BDB001 (DRUG).
Who is sponsoring clinical trial NCT04819373?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04819373's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI